Analysts forecast that Dova Pharmaceuticals Inc (NASDAQ:DOVA) will announce sales of $4.79 million for the current quarter, according to Zacks. Four analysts have made estimates for Dova Pharmaceuticals’ earnings, with estimates ranging from $4.00 million to $5.67 million. The company is expected to issue its next earnings report on Thursday, February 21st.

According to Zacks, analysts expect that Dova Pharmaceuticals will report full-year sales of $12.18 million for the current fiscal year, with estimates ranging from $11.00 million to $13.18 million. For the next year, analysts forecast that the business will post sales of $58.85 million, with estimates ranging from $41.00 million to $74.92 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Dova Pharmaceuticals.

Dova Pharmaceuticals (NASDAQ:DOVA) last announced its quarterly earnings data on Thursday, November 8th. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.12. The company had revenue of $2.93 million for the quarter, compared to analyst estimates of $2.66 million.

Several analysts have recently commented on the stock. Zacks Investment Research raised shares of Dova Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 price objective for the company in a research report on Wednesday, October 10th. BidaskClub upgraded Dova Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 24th. Raymond James started coverage on Dova Pharmaceuticals in a report on Wednesday, August 29th. They issued an “outperform” rating and a $44.00 target price on the stock. Finally, Leerink Swann cut their target price on Dova Pharmaceuticals from $32.00 to $31.00 and set a “market perform” rating on the stock in a report on Tuesday, September 4th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $33.20.

Several institutional investors and hedge funds have recently modified their holdings of DOVA. Metropolitan Life Insurance Co. NY bought a new position in shares of Dova Pharmaceuticals in the 2nd quarter worth $128,000. Stonepine Capital Management LLC bought a new position in shares of Dova Pharmaceuticals in the 3rd quarter worth $145,000. Tower Research Capital LLC TRC bought a new position in shares of Dova Pharmaceuticals in the 3rd quarter worth $158,000. Bank of America Corp DE lifted its holdings in shares of Dova Pharmaceuticals by 81.3% in the 2nd quarter. Bank of America Corp DE now owns 5,305 shares of the company’s stock worth $159,000 after purchasing an additional 2,379 shares in the last quarter. Finally, MetLife Investment Advisors LLC bought a new position in shares of Dova Pharmaceuticals in the 2nd quarter worth $181,000. Institutional investors own 37.14% of the company’s stock.

Shares of DOVA stock traded down $0.29 during trading hours on Monday, hitting $14.42. 4,590 shares of the company were exchanged, compared to its average volume of 191,923. The company has a market cap of $414.88 million, a price-to-earnings ratio of -10.29 and a beta of 0.71. Dova Pharmaceuticals has a fifty-two week low of $14.09 and a fifty-two week high of $37.00. The company has a quick ratio of 7.40, a current ratio of 7.50 and a debt-to-equity ratio of 0.17.

About Dova Pharmaceuticals

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.

Further Reading: What does earnings per share mean?

Get a free copy of the Zacks research report on Dova Pharmaceuticals (DOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.